|1.||Harrison, Thomas S: 12 articles (12/2015 - 05/2004)|
|2.||Kim, Seung U: 8 articles (01/2014 - 01/2009)|
|3.||Kasahara, Noriyuki: 7 articles (02/2015 - 01/2003)|
|4.||Hamada, H: 7 articles (08/2012 - 01/2000)|
|5.||Altaner, Cestmir: 6 articles (09/2014 - 07/2007)|
|6.||Jarvis, Joseph N: 5 articles (12/2015 - 04/2008)|
|7.||Loyse, Angela: 5 articles (12/2015 - 07/2008)|
|8.||Altanerova, Veronika: 5 articles (03/2014 - 07/2007)|
|9.||Aboody, Karen S: 5 articles (01/2014 - 12/2003)|
|10.||Matuskova, Miroslava: 5 articles (07/2013 - 07/2007)|
06/01/1975 - "The fungi infection was successfully eradicated by a single oral dose of 5-Fluorocytosine (20 mg/kg) after each dialysis treatment. "
01/01/1995 - "Flucytosine is effective in the treatment of serious fungal infections. "
08/01/1984 - "The combination of bursectomy and flucytosine treatment cured the infection."
08/01/1978 - "The infection responded well to treatment with 5-fluorocytosine. "
11/01/1975 - "No resistance to 5-fluorocytosine developed, and the candida infection was eradicated. "
11/01/2013 - "Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal."
04/01/2003 - "Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?"
08/01/1998 - "Flucytosine (5-FC) monotherapy for cryptococcosis is not advocated because drug resistance emerges during therapy. "
08/01/1998 - "Flucytosine monotherapy for cryptococcosis."
01/19/1980 - "[Treatment of cryptococcosis with flucytosine]."
10/01/2007 - "The present study demonstrated the substantial increasing of survival time of HIV-infected patients with cryptococcal meningitis by initiated ART even in a resource limited setting (no flucytosine, local combined antiretroviral drugs with NVP based regimens)."
09/01/2014 - "Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need."
03/01/2012 - "Herein, we present a case of cryptococcal meningitis from China, which was caused by an azole and flucytosine resistant Filobasidium uniguttulatum. "
07/01/2008 - "Sixty-four HIV-seropositive, antiretroviral therapy-naive patients in Cape Town, South Africa, who experienced their first episode of cryptococcal meningitis during the period May 2005-June 2006 were randomized to receive either (1) AmB, 0.7 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 1; 30 patients); or (2) AmB, 1 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 2; 34 patients). "
03/01/2007 - "Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis."
10/01/2009 - "Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis."
09/01/1988 - "[Clinical efficacy of flucytosine on urinary candidiasis]."
01/01/1985 - "In a previous study with flucytosine (5-FC) susceptibility of 40 Candida albicans isolates in vitro proved statistically correlated with response in systemic murine candidiasis in vivo, although exceptions occurred with individual isolates. "
11/01/2006 - "We used a pharmacodynamic model of disseminated candidiasis to define an in vivo drug exposure breakpoint for flucytosine (5FC) against Candida albicans. "
11/01/2005 - "For acute disseminated candidiasis, the combination of DAMB plus flucytosine is recommended. "
|5.||Acquired Immunodeficiency Syndrome (AIDS)
10/01/1999 - "Disseminated acanthamoeba infection in a patient with AIDS: response to 5-fluorocytosine therapy."
12/09/1988 - "Anaphylaxis to flucytosine in a patient with AIDS."
06/01/1998 - "These data indicate that treatment with fluconazole and short-term flucytosine is a cost-effective and safe regimen that improves the quality of life for patients with AIDS-associated CM in developing countries where human immunodeficiency virus is endemic."
04/01/1988 - "Mycological-diagnostic assessment of the efficacy of amphotericin B + flucytosine to control Cryptococcus neoformans in AIDS patients."
02/01/1995 - "Thirty-one consecutive AIDS patients with cryptococcal disease were enrolled in a study of the efficacy and safety of short-course primary treatment with a relatively high dose of amphotericin B (1 mg/[kg.d] for 14 days); 26 patients also received flucytosine (100-150 mg/[kg.d], given either intravenously or orally). "
|1.||Amphotericin B (Amphotericin)
|5.||liposomal amphotericin B
|1.||Transplantation (Transplant Recipients)
|2.||Drug Therapy (Chemotherapy)